MedTrace Logo

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

NCT05592626 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2025-07-09

No results posted yet for this study

Summary

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.

Conditions

  • Advanced Solid Tumors
  • Genital Neoplasm, Female
  • Urogenital Neoplasms
  • Lung Neoplasm
  • Neoplasms by Site
  • Papillomavirus Infection
  • Epstein-Barr Virus Infections
  • Carcinoma
  • Neoplasms
  • Vulvar Neoplasms
  • Vulvar Diseases
  • Abdominal Neoplasm

Interventions

DRUG

STAR0602

solution, intravenous infusion

Sponsors & Collaborators

  • Marengo Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-04
Primary Completion
2026-10-31
Completion
2026-10-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05592626 on ClinicalTrials.gov